These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38369231)

  • 1. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
    Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
    Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases.
    Xue K; MacLaren RE
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1163-1170. PubMed ID: 32741234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
    Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
    Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway.
    Liang XH; Nichols JG; Hsu CW; Vickers TA; Crooke ST
    Nucleic Acids Res; 2019 Jul; 47(13):6900-6916. PubMed ID: 31165876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.
    Collin RW; Garanto A
    Curr Opin Ophthalmol; 2017 May; 28(3):260-266. PubMed ID: 28151748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-based therapies in inherited retinal diseases.
    Girach A; Audo I; Birch DG; Huckfeldt RM; Lam BL; Leroy BP; Michaelides M; Russell SR; Sallum JMF; Stingl K; Tsang SH; Yang P
    Ther Adv Ophthalmol; 2022; 14():25158414221134602. PubMed ID: 36388727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
    Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
    Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting nuclear RNA for in vivo correction of myotonic dystrophy.
    Wheeler TM; Leger AJ; Pandey SK; MacLeod AR; Nakamori M; Cheng SH; Wentworth BM; Bennett CF; Thornton CA
    Nature; 2012 Aug; 488(7409):111-5. PubMed ID: 22859208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides.
    Ward AJ; Norrbom M; Chun S; Bennett CF; Rigo F
    Nucleic Acids Res; 2014 May; 42(9):5871-9. PubMed ID: 24589581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bestrophin1: A Gene that Causes Many Diseases.
    Smith JJ; Nommiste B; Carr AF
    Adv Exp Med Biol; 2019; 1185():419-423. PubMed ID: 31884648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for inherited retinal diseases: progress and possibilities.
    Hu ML; Edwards TL; O'Hare F; Hickey DG; Wang JH; Liu Z; Ayton LN
    Clin Exp Optom; 2021 May; 104(4):444-454. PubMed ID: 33689657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities.
    Schneider N; Sundaresan Y; Gopalakrishnan P; Beryozkin A; Hanany M; Levanon EY; Banin E; Ben-Aroya S; Sharon D
    Prog Retin Eye Res; 2022 Jul; 89():101029. PubMed ID: 34839010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.
    Yasuhara H; Yoshida T; Sasaki K; Obika S; Inoue T
    Mol Diagn Ther; 2022 Jan; 26(1):117-127. PubMed ID: 34994962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
    Hori SI; Mitsuoka Y; Kugimiya A
    Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS.
    Østergaard ME; Southwell AL; Kordasiewicz H; Watt AT; Skotte NH; Doty CN; Vaid K; Villanueva EB; Swayze EE; Bennett CF; Hayden MR; Seth PP
    Nucleic Acids Res; 2013 Nov; 41(21):9634-50. PubMed ID: 23963702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.